SMMT vs. ALNY, GMAB, TEVA, RPRX, BGNE, BMRN, VTRS, UTHR, RDY, and SRPT
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alnylam Pharmaceuticals currently has a consensus target price of $216.19, suggesting a potential upside of 42.10%. Summit Therapeutics has a consensus target price of $13.50, suggesting a potential upside of 69.39%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals received 803 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 57.17% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -16.58%. Summit Therapeutics' return on equity of 0.00% beat Alnylam Pharmaceuticals' return on equity.
Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500.
In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Alnylam Pharmaceuticals and 4 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.45 beat Alnylam Pharmaceuticals' score of 0.56 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
Alnylam Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Alnylam Pharmaceuticals beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
